SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Sarafidis, Pantelis; Ferro, Charles J.; Morales, Enrique; Ortiz, Alberto; Malyszko, Jolanta; Hojs, Radovan; Khazim, Khaled; Ekart, Robert; Valdivielso, Jose; Fouque, Denis; London, Gérard M.; Massy, Ziad; Ruggenenti, Petro; Porrini, Esteban; Wiecek, Andrej; Zoccali, Carmine; Mallamaci, Francesca; Hornum, Mads. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2019; 34: p.208-230. doi:10.1093/ndt/gfy407
Article